怀孕前感觉 葡萄糖类-1受体激素的使用与不良产科结果的风险降低有关
Marisa R Imbroane1, Felicia LeMoine2, Christopher T Nau3
1School of Medicine, Case Western Reserve University, Cleveland, OH.
American journal of obstetrics and gynecology
|January 23, 2025
概括
在怀孕前使用的类似葡萄糖-1受体激动剂与妊娠糖尿病和早产等不良结果的减少有关. 这表明,对高风险个体的围产期健康有潜在的益处.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 产科和妇科 产科和妇科
- 药理学 药理学是指药理学的学科.
背景情况:
- 在生育年龄的妇女中,越来越多地使用类似葡萄糖-1受体激活剂 (GLP-1RA).
- 关于GLP-1RA对怀孕结果的长期影响的数据有限.
研究的目的:
- 研究GLP-1RA在受孕前使用与不良产科结果之间的关联.
- 利用一个庞大的,具有全国代表性的医疗保健数据库进行全面分析.
主要方法:
- 追溯队列研究设计,涉及18岁及以上的女性患者.
- 在怀孕前两年内与没有GLP-1RA处方的队列的比较.
- 根据主要的人口和临床因素进行匹配;分析结果,包括妊娠糖尿病,高血压疾病,早产和剖腹产.
主要成果:
- GLP-1 RA使用与妊娠糖尿病的显著较低率相关 (OR 0.81,95% CI 0.72-0.91).
- 孕期高血压疾病 (OR 0.84,95% CI 0.76-0.94) 和早产 (OR 0.68,95% CI 0.54-0.85) 的几率有所降低.
- 在GLP-1 RA组中,剖腹产的可能性也较低 (OR 0.89,95% CI 0.87-0.97).
结论:
- 预想 GLP-1 RA 使用与重大不良产科结果风险降低相关.
- 在高危人群中,GLP-1RA可能是优化围产期健康的有价值策略.
- 需要进一步的研究来指导GLP-1RA在孕前护理中的临床整合.
相关概念视频
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Pathophysiology of Diabetes
854
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
854
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165


